Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Preventing the next event in the elderly: the PROSPER perspective.

James Shepherd1

  • 1Department of Pathological Biochemistry, University Department of Pathological Biochemistry, Royal Infirmary, Glasgow, G4 0SF, Scotland, UK. jshepherd@gri-biochem.org.uk

Atherosclerosis. Supplements
|February 26, 2004
PubMed
Summary

Pravastatin statin therapy effectively reduced coronary heart disease risk in elderly individuals over three years. This study, PROSPER, confirms statin benefits for older adults, similar to middle-aged populations.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Utilizing Internet Search Trends and Wastewater Surveillance to Identify Infectious Disease Outbreaks in Communities.

Environmental science & technology·2025
Same author

Tact.

International dental journal (Philadelphia, Pa.)·2023
Same author

Risk factors for Crimean-Congo Haemorrhagic Fever (CCHF) virus exposure in farming communities in Uganda.

The Journal of infection·2022
Same author

Mapping bare ground in New Zealand hill-country agriculture and forestry for soil erosion risk assessment: An automated satellite remote-sensing method.

Journal of environmental management·2021
Same author

Non-epidemic HCV genotypes in low- and middle-income countries and the risk of resistance to current direct-acting antiviral regimens.

Journal of hepatology·2021
Same author

Genetic epidemiology of SARS-CoV-2 transmission in renal dialysis units - A high risk community-hospital interface.

The Journal of infection·2021

Area of Science:

  • Cardiovascular Medicine
  • Geriatric Medicine
  • Pharmacology

Background:

  • Statins are proven to reduce cardiovascular events in middle-aged individuals.
  • Efficacy and safety of statins in the elderly population remained unconfirmed.
  • Previous trials sub-analyzed elderly cohorts, but PROSPER specifically targeted this demographic.

Purpose of the Study:

  • To evaluate the benefits and risks of statin therapy (pravastatin) in elderly individuals.
  • To assess the impact of pravastatin on vascular risk in men and women aged 70 years and older.
  • To determine if statin therapy could be extended as a treatment strategy for the elderly.

Main Methods:

  • The Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) trial.
  • Involved elderly men and women, evaluating pravastatin over three years.

Related Experiment Videos

  • Assessed outcomes including coronary heart disease, stroke, and transient ischemic attacks.

    • Main Results:

    • Pravastatin significantly reduced the risk of coronary heart disease in the elderly.
    • No significant reduction in stroke risk was observed, though a trend towards reducing transient ischemic attacks was noted.
    • Patients with the lowest baseline high-density lipoprotein cholesterol levels experienced the greatest benefit.
    • Drug interactions were not a significant clinical issue in this cohort.

    Conclusions:

    • Pravastatin therapy is beneficial for reducing coronary heart disease risk in elderly individuals.
    • The findings support extending statin treatment strategies to the elderly population.
    • PROSPER provides evidence for the efficacy and safety of statins in older adults.